MedTrace Logo

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

NCT06503094 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-07-16

No results posted yet for this study

Summary

This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.

Conditions

  • B-Cell Lymphoblastic Leukemia/Lymphoma

Interventions

DRUG

CD19&CD20 bispecific CAR-T cells

Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.

Sponsors & Collaborators

  • Hebei Taihe Chunyu Biotechnology Co., Ltd

    collaborator INDUSTRY

  • Zhujiang Hospital

    collaborator OTHER

  • Jingzhou Central Hospital

    collaborator OTHER

  • Shiyan People's Hospital

    collaborator UNKNOWN

  • Xiangyang Central Hospital

    collaborator OTHER

  • Yichang Central People's Hospital

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Mei Heng · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-14
Primary Completion
2025-12-18
Completion
2026-06-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06503094 on ClinicalTrials.gov